Anagrelide CR — Competitive Intelligence Brief

Anagrelide CR (Anagrelide CR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: platelet aggregation inhibitor. Area: Cardiovascular.

phase 2 platelet aggregation inhibitor cAMP Cardiovascular Small molecule

Target snapshot

Anagrelide CR (Anagrelide CR) — Galena Biopharma, Inc.. Anagrelide CR works by inhibiting platelet aggregation and reducing platelet count.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anagrelide CR TARGET	Anagrelide CR	Galena Biopharma, Inc.	phase 2	platelet aggregation inhibitor	cAMP
Daliresp	ROFLUMILAST	Arcutis	marketed	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	2011-01-01
Campath	ALEMTUZUMAB	Sanofi	marketed	CD52-directed Cytolytic Antibody [EPC]	CAMPATH-1 antigen	2001-01-01
Leustatin	CLADRIBINE		marketed	Purine Antimetabolite [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1993-01-01
Ketas	IBUDILAST	Kyorin Pharmaceutical	marketed	ibudilast	cAMP-specific 3',5'-cyclic phosphodiesterase 4A	1989-01-01
Diphyllin	diprophylline		marketed	diprophylline	cAMP-specific 3',5'-cyclic phosphodiesterase 4B	1951-01-01
Otezla	Otezla	L.H. Kircik, M.D.	marketed		cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2038-11-23 — Leustatin · 10849919 · Method of Use · US
• 2041-09-10 — Leustatin · 12533408 · Method of Use · US
• 2041-09-10 — Leustatin · 12539329 · Method of Use · US

Sponsor landscape (platelet aggregation inhibitor class)

1. Galena Biopharma, Inc. · 1 drug in this class